Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead

Key Points

• Povetacicept is Vertex’s key near-term catalyst, with an FDA PDUFA decision for IgA nephropathy scheduled for Nov. 30. The company is positioning the therapy around dual APRIL/BAFF targeting, monthly low-volume dosing and a large renal sales force.
• Vertex is expanding its renal pipeline beyond IgAN, with a Phase III membranous nephropathy readout ahead and potential data from inaxaplin studies for APOL1-mediated kidney disease expected over the next year.
• Cystic fibrosis remains the company’s core growth engine as Vertex expands ALYFTREK globally and into younger patients, while also advancing rare endocrine medicines, CASGEVY, cell therapies for type 1 diabetes and next-generation pain treatments.

Vertex Pharmaceuticals NASDAQ: VRTX is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s priorities, CEO and President Reshma Kewalramani said at Morgan Stanley’s 24th Annual Healthcare Conference.

Kewalramani said cystic fibrosis remains a foundational growth pillar as the company expands the global rollout of ALYFTREK, pursues access in additional countries and develops the treatment for younger patients. She also highlighted progress for CASGEVY, the company’s gene-editing therapy, and JOURNAVX, its non-opioid medicine for acute pain.

Following the acquisition of Crinetics, Kewalramani identified rare endocrine disease as Vertex’s fourth pillar, citing PALSONIFY for acromegaly and atumelnant, an investigational treatment being developed for congenital adrenal hyperplasia and Cushing’s disease. She said the company sees atumelnant as having multibillion-dollar potential.

Renal Pipeline Takes Center Stage

A principal near-term catalyst is povetacicept, Vertex’s investigational therapy for IgA nephropathy, or IgAN. Kewalramani said the U.S. Food and Drug Administration’s Prescription Drug User Fee Act date for the treatment is Nov. 30.

She said Vertex believes povetacicept can differentiate itself in a competitive IgAN market through its dual targeting of APRIL and BAFF, cytokines involved in B-cell development and maturation. Kewalramani also pointed to the therapy’s monthly, low-volume autoinjector administration, saying the 0.46-milliliter dose could be an important convenience factor for patients expected to remain on treatment long term.

The CEO cautioned that comparisons between studies are cross-trial and numerical, but said povetacicept showed the strongest numerical results on measures including proteinuria, hematuria and Gd-IgA1 levels. Vertex has also built what Kewalramani described as the largest sales force among companies entering the renal category, with the aim of reaching specialists, large clinics and community-based patients.

Vertex plans to continue the povetacicept study through two-year kidney-function follow-up rather than disclose glomerular filtration rate, or GFR, data earlier. Kewalramani said the decision reflects the company’s goal of pursuing global approvals, as regulators outside the U.S. have not broadly accepted proteinuria as an accelerated-approval endpoint and may require two-year GFR data.

Beyond IgAN, Vertex expects a Phase III readout for povetacicept in membranous nephropathy to be the next major program update. The company is also studying the treatment in myasthenia gravis in Phase II.

Inaxaplin Studies Approach Data Readouts

Kewalramani also discussed inaxaplin, Vertex’s investigational treatment for APOL1-mediated kidney disease, or AMKD. The disease affects people of recent Sub-Saharan African descent and is associated with a substantially higher risk of progressive kidney disease in individuals with two APOL1 alleles, she said.

Vertex estimates that 100,000 to 150,000 people in the U.S. have AMKD, a condition for which no medicine has been specifically approved. The company’s Phase III AMPLITUDE trial is expected to produce an interim analysis in early next year, with potential accelerated approval tied to one-year GFR data. Enrollment for the full cohort is expected to finish in the second half of this year.

A separate Phase IIb study, AMPLIFY, is expected to report results in the fall. It includes patients with modest proteinuria and a cohort of patients with both AMKD and type 2 diabetes. Kewalramani said a proteinuria reduction in the 20% to 30% range would be positive in the modest-proteinuria cohort, although she declined to specify a formal success threshold.

Vertex has been supporting genetic-testing efforts to help identify potential AMKD patients, including through an arrangement involving Natera’s genetic kidney disease testing. Kewalramani said the company has identified patients through testing programs that have operated for several years and expects disease awareness and testing to be central to the eventual commercial strategy if inaxaplin is approved.

Cystic Fibrosis Growth and Earlier-Stage Programs

In cystic fibrosis, Kewalramani said ALYFTREK has regulatory approval in most regions, though pricing and reimbursement discussions continue in some markets. Vertex is working to transition eligible patients from TRIKAFTA to the once-daily therapy, reach patients with certain ultra-rare mutations and expand treatment to children ages 2 to 5 before moving into still younger groups.

The company is also pursuing reimbursement in emerging markets, including Brazil and Turkey. While pricing pressure remains a feature of certain international markets, Kewalramani said Vertex has been able to maintain pricing in some countries by presenting real-world evidence showing stable lung-function outcomes.

Vertex is advancing additional cystic fibrosis candidates under its Next Gen 3.0 program, including VX-828, VX-581 and VX-272, while earlier research continues on future generations of therapies.

Other pipeline priorities include cell therapies for type 1 diabetes. Kewalramani said an investigational Type O program has cleared its investigational new drug application, enabling patient dosing in a Phase I/II study. She also cited a late-preclinical program combining NaV1.7 and NaV1.8 targets for pain treatment.

About Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development.

Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.